New Approach in Delivering Chemotherapy: Locoregional Treatment for Recurrent Glioblastoma (rGBM)

Amerigo Boiardi, M. Eoli, A. Salmaggi, E. Lamperti, A. Botturi, G. Broggi, M. Bartolomei, A. Silvani

Research output: Contribution to journalArticle

Abstract

The treatment of GBM tumor recurrence is generally a hopeless challenge, since recurred tumor is resistant to the most common therapeutic efforts. Some partial results can be achieved by targeting local disease control, in view of the fact that 95% of recurrences occur locally. We present results concerning three pilot studies, all performed in recurrent GBM patients who underwent second surgery and have been treated systemically with temozolomide and locally through an Ommaya reservoire according to the following schedules: a) in 20 rGBM, 4 mg novantrone was delivered day 1,5 every 30 days; in 26 rGBM, 4 mg novantrone was delivered every 20 days in association with locoregional radioimmunotherapy (RIT); in 12 rGBM pegylated liposomal doxorubicin 4 mg was delivered day 1,5,10,15,20 with 20 days interval. Results seem very promising since there is an extension of disease free and survival, both of more than 50% if results are evaluated in relation with the most frequent data of the literature.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalJournal of Experimental and Clinical Cancer Research
Volume22
Issue number4 SUPPL.
Publication statusPublished - Dec 2003

Keywords

  • Glioblastoma recurrence
  • Local chemotherapy
  • Locoregional radioimmunotherapy
  • Mitoxantrone
  • Pegylated doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'New Approach in Delivering Chemotherapy: Locoregional Treatment for Recurrent Glioblastoma (rGBM)'. Together they form a unique fingerprint.

  • Cite this